Background: Worldwide, hemoglobinopathies affect millions of children. Identification of hemoglobin disorders in most sub-Saharan African countries is delayed until clinical signs of the disease are present. Limited studies have been conducted to understand their prevalence and clinical presentation among newborns in resource-limited settings.
INTRODUCTION
Hemoglobinopathies, such as sickle cell disease (SCD), and thalassemia are genetically inherited, widely distributed, and affect millions of people around the world. 1 Of the estimated 330,000 neonates who are born worldwide annually with a major hemoglobinopathies, 275,000
Abbreviations: CBC, complete blood count; HPLC, high-performance liquid chromatography; LTFU, loss to follow-up; RDW, red cell distribution width; SCD, sickle cell disease; SCT, sickle cell trait; SSA, sub-Saharan Africa have SCD, and the overwhelming majority of these are born in subSaharan Africa (SSA). 2 Mortality related to SCD and thalassemia is highest in the first 3 years of life. 3, 4 In rural parts of SSA, most children with SCD die before the age of 5. 5 In urban centers in SSA, great gains have been made, but early childhood mortality is still 10 times higher than the United States. [6] [7] [8] Hemoglobinopathies are responsible for 6 .4% of all mortality among children under 5 years of age in SSA. 2 To address this high mortality rate, the World Health Organization has recommended that countries with a high prevalence of SCD implement a national strategy for diagnosis and treatment, including the creation of a newborn screening program. 9 High-income countries have drastically decreased mortality over the past few decades with the introduction of early infant diagnosis and comprehensive care programs. 10 Because of economic constraints, newborn screening of hemoglobin disorders in most SSA countries has been limited, and diagnosis is often delayed until children present with clinical signs of disease.
Tanzania has the third highest number of SCD-related births in the world annually. Tanzania does not have a national newborn screening policy, but it has taken great strides in the diagnosis and management of SCD, recognizing its public health importance and creating national guidelines for care of people affected by SCD. [11] [12] [13] Most of the research and clinical care has been focused in the coastal city of Dar es Salaam at the national hospital. 7, 14 We have previously reported the high morbidity from SCD in the Northwestern part of the country where the sickle cell gene is thought to be most prevalent. 15, 16 However, estimates of SCD prevalence are based primarily on small adult populations conducted half a century ago, 17, 18 and recent reports have shown that SCD prevalence based on Hardy-Weinberg equilibrium from such studies are unreliable. 19 Therefore, we conducted a study to understand the extent of hemoglobinopathies, specifically to generate baseline information on its prevalence and clinical pattern among newborns in two selected hospitals in Northwestern Tanzania. Our secondary objective was to understand the changes in hematological parameters in those affected by hemoglobinopathies compared to unaffected newborns. These data will provide a foundation for planning a coordinated public health response that targets interventions at the populations most affected by SCD. This will result in reduction of morbidity and improved survival of the affected children. BMC has a sickle cell clinic which has >400 children enrolled. The clinic runs once a week, and about 30 patients are seen on a weekly basis.
METHODS

Study area and recruitment
Most of the children report to the clinic after development of complications such as dactylitis, recurrent fever, or vaso-occlusive crisis. Children with SCD at BMC are provided an insecticide-treated bed net (ITN) and prescribed daily folic acid and penicillin. Formerly, chloroquine was prescribed for malaria prophylaxis, but this was stopped due 
Laboratory methods
Peripheral venous blood was collected in ethylenediaminetetraacetic acid tubes at enrolment from all neonates and at 3 and 6 month followup visits from infants enrolled in the follow-up phase. A CBC was performed using the Cell-Dyn 3700 Hematology Analyzer (Abbott Diagnostics, Lake Bluff, IL) at STH. Samples were shipped to the Muhimbili University of Health and Allied Sciences sickle cell laboratory for hemoglobinopathy screening using high-performance liquid chromatography (HPLC). HPLC was performed using the Variant I Haemoglobin Testing System (Bio-Rad Laboratories, Inc., Hercules, CA) under the experimental conditions specified by the manufacturer. The principle, reagents, sample collection and preparation, and interpretation of reports of HPLC have already been explained elsewhere. 20, 21 + -Thalassemia was diagnosed when the peak in the A 2 window was >4.0%.
Data analysis
Data were analyzed using STATA version 12 (Stata Corp, College Station, TX). Differences in proportion were analyzed using a chi-squared 
Ethical issues
Ethical clearance for this study was obtained from the com- prophylaxis, and registered to attend our sickle cell clinic at BMC.
RESULTS
Enrolment and follow-up
A total of 2,280 deliveries occurred during the period of enrolment:
1,300 at BMC and 980 at STH. 
Prevalence of hemoglobinopathies
The distribution of hemoglobin variants identified among the study participants is shown in Figure 3 . 
Clinical characteristics at baseline and follow-up
The median age was 2 days (interquartile range, 1-2 days) ( Table 1 ). Table S1 ). None of the other parameters differed between the groups.
Hematological parameters at baseline and follow-up
The percent of fetal hemoglobin was measured in blood samples at baseline and at 3-month follow-up. The baseline mean percent of fetal hemoglobin was significantly higher in the Hb FS group (84.7%) compared to the Hb FA (76.3%) and Hb FAS (77.6%) groups (P < 0.001). At 3-month follow-up, the percent of fetal hemoglobin remained higher in the Hb FS group (61.2%) than the Hb FA (34.9%) and Hb FAS (31%) groups (P < 0.001) ( Table 2) .
A CBC was performed at baseline, 3-month, and 6-month follow-up to compare the hematological indices at these time points. The baseline values and the erythrocyte indices that were significantly different at 3 and 6 months are provided in Table 2 . At baseline, the Hb FA, Hb FAS, and Hb FS groups had no significant difference in their erythrocyte indices other than the mean corpuscular volume, which was slightly smaller in the Hb FAS group (P = 0.04), and the red cell distribution width (RDW), which was slightly smaller in the FA group (P < 0.001). Leucocytes were significantly lower in the Hb FS group compared to Hb FA and Hb FAS (P = 0.019). RDW (18.34 ± 4.04). This was significantly higher than the RDW of the Hb FA group (15.25 ± 5.70) when the two were compared individually (P = 0.003). In addition, the red cell number and hematocrit were now significantly different between the three groups. Both were lowest in the Hb FS group.
At baseline, neonates in the different groups had a similar mean hemoglobin ranging from 16.7 g/dl (Hb FA) to 17.7 g/dl (Hb FS) (P = 0.58). At 3-month follow-up, a decline in the mean hemoglobin was observed in each group, but the difference between the mean hemoglobins in each group remained similar (P = 0.11). The decline in hemoglobin was more pronounced among neonates with SCD (from 17.7 to 8.6 g/dl) compared to both normal neonates (from 16.7 to 10.2 g/dl) and neonates with SCT (16.8 to 10.0 g/dl). At 6 months, mean hemoglobin was significantly different between each of the groups (P = 0.016). A further decline in mean hemoglobin was observed in those with SCD and SCT, 7.9 g/dl in those with SCD compared to 9.6 g/dl in those with SCT. There was a slight increase in mean hemoglobin to 10.4 g/dl in normal infants (Fig. 4) . 
DISCUSSION
The birth prevalence of hemoglobinopathies in Northwestern Tanzania is extremely high with 1.4% of children born with Hb FS and onethird of children carrying a significant hemoglobin variant. This is three times higher than the rates reported at the national hospital in the coastal city of Dar es Salaam 22 as well as the most recent report among newborns in Northwestern Tanzania, 23 both of which reported Hb FS in only 0.5% of births. We confirm high extrapolated estimates based on older adult populations from around Lake Victoria. 17, 18 The Northwestern part of the country continues to experience selective pressure for the Hb S allele as it has continuous transmission of malaria throughout the year and the highest prevalence of malaria among children in the country. 24 The high prevalence of SCD likely contributes to a significant proportion of under-five mortality in the region, which is the highest in the country. 25 The prevalence we identified is significantly higher than the prevalence in middle-or high-income countries in Latin America, Europe, or the United States. [26] [27] [28] Rather, the prevalence in Northwestern Tanzania is consistent with the highest prevalence areas in SSA such as Nigeria in West Africa (1.6%) or Angola (1.5%) and the Democratic Republic of Congo (1.4%) in Central Africa. [29] [30] [31] A higher prevalence of SCD among newborns has rarely been reported. A smaller crosssectional study at Mulago Hospital Uganda identified Hb FS in 3.9% of newborns, 32 but a more recent nationally representative sample identified the highest prevalence nationally to be 1.5% in the East-Central areas of the country. 33 One study reported a higher prevalence of 2.4% among a smaller sample of newborns at a single center in southern Nigeria. 34 The high prevalence of hemoglobinopathies in Northwestern Tanzania establishes SCD and other hemoglobinopathies as problems of major public health importance that must be addressed if improvements in child survival are to be achieved. If limited funding to address SCD is available to address this threat, policies for prevention and management of SCD through screening and early preventive care ought to be established first in areas of highest prevalence. Newborn screening programs are among the most cost effective. 35, 36 They provide the opportunity for parental education regarding care of the affected child as well as communication regarding the risk of future conceptions being affected. It also allows mothers who were previously undiagnosed to establish care for their own SCD.
The most important hematological changes over the course of follow-up in this study were the hemoglobin and RDW. At birth, the neonates with sickle cell anemia had normal red blood cell indices because of the impact of fetal hemoglobin. However, at 3 months, infants with sickle cell anemia had a pronounced drop in their hemoglobin and increase in RDW. This is expected as the neonates with Hb FS are undergoing an increased rate of hemolysis as they lose fetal hemoglobin and increase the percent of abnormal beta globin. Subsequent hemolysis due to the polymerization of hemoglobin and deformation of the red blood cell shortens the half-life of sickled cells to 10-20 days. 7,31,37 Our study confirms that this change in hematological profile occurs as early as 3 months of age even in the absence of the clinical phenotypic changes associated with sickle cell anemia such as painful crises or dactylitis. These findings confirm observations in other studies and suggest that a pronounced anemia in neonates should prompt further investigations, especially when hemoglobinopathies are suspected. 38 Our study had several limitations. While a few clinical complications due to hemoglobin variants in children may be present before 6 months of age, most of the complications appear after 6 months.
Because children with fever often reported to hospitals other than the study site, we were unable to determine the cause of fever in children with sickle cell anemia. A longitudinal study is needed to establish the effect of hemoglobinopathies in children in SSA. HPLC is a promising diagnostic tool as an initial screening method of hemoglobin variants and is useful at detecting variants, but some rare variants could have been missed on HPLC that would have been detected on capillary electrophoresis. Using the peak in the A 2 window from HPLC to diagnose + -thalassemia is an inaccurate technique and requires supplementary data (e.g., family studies, RBC indices, and capillary electrophoresis) to confirm the diagnosis. Abnormal hemoglobins in our study were not confirmed with a second modality.
CONCLUSION
The prevalence of SCD in Northwestern Tanzania is one of the high- 
